MX2022001343A - Compuestos y composiciones para tratar trastornos hematologicos. - Google Patents

Compuestos y composiciones para tratar trastornos hematologicos.

Info

Publication number
MX2022001343A
MX2022001343A MX2022001343A MX2022001343A MX2022001343A MX 2022001343 A MX2022001343 A MX 2022001343A MX 2022001343 A MX2022001343 A MX 2022001343A MX 2022001343 A MX2022001343 A MX 2022001343A MX 2022001343 A MX2022001343 A MX 2022001343A
Authority
MX
Mexico
Prior art keywords
compounds
hematological disorders
compositions
treating hematological
treating
Prior art date
Application number
MX2022001343A
Other languages
English (en)
Inventor
Susanta Samajdar
Venkateshwar Rao Gummadi
Kavitha Nellore
Girish Daginakatte
Wesley Roy Balasubramanian
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of MX2022001343A publication Critical patent/MX2022001343A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

La presente invención proporciona métodos para tratar trastornos hematológicos, tales como la leucemia mieloide aguda, mediante el uso de compuestos heterocíclicos sustituidos y sales farmacéuticamente aceptables de estos. Los compuestos inhiben las cinasas IRAK4 y FLT-3.
MX2022001343A 2017-03-31 2019-09-19 Compuestos y composiciones para tratar trastornos hematologicos. MX2022001343A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201741011785 2017-03-31

Publications (1)

Publication Number Publication Date
MX2022001343A true MX2022001343A (es) 2022-03-17

Family

ID=63677680

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019011158A MX2019011158A (es) 2017-03-31 2018-03-30 Compuestos y composiciones para tratar trastornos hematologicos.
MX2022001343A MX2022001343A (es) 2017-03-31 2019-09-19 Compuestos y composiciones para tratar trastornos hematologicos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019011158A MX2019011158A (es) 2017-03-31 2018-03-30 Compuestos y composiciones para tratar trastornos hematologicos.

Country Status (24)

Country Link
US (2) US11419875B2 (es)
EP (2) EP3600270B1 (es)
JP (2) JP7333136B2 (es)
KR (2) KR102633530B1 (es)
CN (1) CN110691589A (es)
AU (1) AU2018242623B2 (es)
BR (1) BR112019018991A2 (es)
CA (1) CA3056893A1 (es)
DK (1) DK3600270T3 (es)
EA (1) EA201992322A3 (es)
ES (1) ES2950764T3 (es)
FI (1) FI3600270T3 (es)
HR (1) HRP20230657T8 (es)
HU (1) HUE062648T2 (es)
IL (3) IL305150A (es)
LT (1) LT3600270T (es)
MX (2) MX2019011158A (es)
PH (1) PH12019502138A1 (es)
PL (1) PL3600270T3 (es)
PT (1) PT3600270T (es)
RS (1) RS64411B1 (es)
SG (1) SG11201908171TA (es)
SI (1) SI3600270T1 (es)
WO (1) WO2018178947A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3805233T3 (da) 2014-01-13 2024-04-15 Aurigene Oncology Ltd (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling
KR102633530B1 (ko) 2017-03-31 2024-02-02 오리진 온콜로지 리미티드 혈액 장애를 치료하기 위한 화합물 및 조성물
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
CN114072401B (zh) * 2019-07-10 2023-11-21 南京明德新药研发有限公司 作为irak4和btk多靶点抑制剂的噁唑类化合物
WO2021047677A1 (zh) * 2019-09-12 2021-03-18 中国科学院上海药物研究所 一类irak4激酶抑制剂及其制备和应用
TW202142538A (zh) 2020-02-07 2021-11-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ－１促效劑
AU2021251341A1 (en) 2020-04-07 2022-11-03 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
BR112023001861A2 (pt) * 2020-08-03 2023-03-07 Curis Inc Composições e métodos para tratamento de doenças e distúrbios
CN116745294A (zh) * 2020-12-25 2023-09-12 南京明德新药研发有限公司 酰胺噁唑类化合物
KR20240004476A (ko) * 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 암 치료를 위한 병용 요법
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
WO2023088435A1 (zh) * 2021-11-19 2023-05-25 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
WO2023116866A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
DE59010701D1 (de) 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
JP3979783B2 (ja) 1997-07-29 2007-09-19 アルコン ラボラトリーズ インコーポレイテッド ガラクトマンナンポリマー及びホウ酸塩を含む眼科組成物
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
CN1816529A (zh) 2003-05-01 2006-08-09 布里斯托尔-迈尔斯.斯奎布公司 用作激酶抑制剂的芳基取代的吡唑－酰胺化合物
JP5279987B2 (ja) 2003-05-20 2013-09-04 味の素株式会社 アミド誘導体
EP1628661A2 (en) 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2005032493A2 (en) 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
CA2563941C (en) 2004-04-22 2014-10-07 Bayer Cropscience Lp Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
ES2333243T3 (es) 2004-12-17 2010-02-18 Eli Lilly And Company Derivados de tiazolopiridinona como antagonistas del receptor de mch.
PT1828177E (pt) * 2004-12-17 2008-10-28 Lilly Co Eli Novos antagonistas dos receptores da mch
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
EP2295432A1 (en) 2006-02-10 2011-03-16 TransTech Pharma Inc. Process for the preparation of aminobenzimidazole derivatives
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
EP2001480A4 (en) 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
WO2007121154A2 (en) 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
WO2008030579A2 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
NZ575410A (en) 2006-09-07 2012-03-30 Biogen Idec Inc 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives
US20080153810A1 (en) 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
JP2010529195A (ja) * 2007-06-14 2010-08-26 シェーリング コーポレイション プロテインキナーゼの阻害剤としてのイミダゾピラジン
US8110572B2 (en) 2007-07-16 2012-02-07 Abbott Laboratories Inhibitors of protein kinases
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009019167A1 (en) 2007-08-08 2009-02-12 Merck Serono S.A. 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis
AU2009215191A1 (en) 2008-02-13 2009-08-20 Gilead Connecticut, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
US20110178070A1 (en) * 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
US8716312B2 (en) 2008-11-19 2014-05-06 Merck Sharp & Dohme Corporation Inhibitors of diacylglycerol acyltransferase
WO2010071819A1 (en) 2008-12-19 2010-06-24 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
CN102264701A (zh) 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮脲
US8765747B2 (en) * 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US20130035326A1 (en) 2009-08-19 2013-02-07 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
CN102656141B (zh) 2009-10-13 2016-04-06 利亘制药公司 模拟造血生长因子的小分子化合物及其用途
EP2560962B1 (en) 2010-04-22 2015-05-20 Janssen Pharmaceutica NV Indazole compounds useful as ketohexokinase inhibitors
WO2011137219A1 (en) 2010-04-30 2011-11-03 Schering Corporation Inhibitors of phosphoinositide dependent kinase 1 (pdk1)
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
CN110003219A (zh) 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
PL2730564T3 (pl) 2010-11-19 2018-09-28 Ligand Pharmaceuticals Inc. Heterocykliczne aminy i ich zastosowania
AU2011347711B2 (en) 2010-12-20 2017-02-02 Merck Serono S.A. Indazolyl triazole derivatives as IRAK inhibitors
CN103608017B (zh) 2011-04-12 2017-02-15 美国卫生和人力服务部 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
KR102066297B1 (ko) * 2011-10-14 2020-01-14 암비트 바이오사이언시즈 코포레이션 헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR101385603B1 (ko) 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en) 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
US9085586B2 (en) 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
WO2014070979A1 (en) 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
CA2907960C (en) 2013-05-22 2021-10-19 Children's Hospital Medical Center Combination therapy for mds
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EA201691401A1 (ru) 2014-01-10 2016-11-30 Ориджин Дискавери Текнолоджиз Лимитед Индазольные соединения в качестве ингибиторов irak4
DK3805233T3 (da) 2014-01-13 2024-04-15 Aurigene Oncology Ltd (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling
CA2938719A1 (en) 2014-02-06 2015-08-13 Abbvie, Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
CN106456609A (zh) 2014-06-20 2017-02-22 奥瑞基尼探索技术有限公司 作为irak4抑制剂的取代的吲唑化合物
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
US20180208605A1 (en) 2015-07-15 2018-07-26 Aurigene Discovery Technologies Limited Substituted Aza Compounds as IRAK-4 Inhibitors
KR20180025896A (ko) 2015-07-15 2018-03-09 오리진 디스커버리 테크놀로지스 리미티드 Irak-4 저해제로서 인다졸 및 아자인다졸 화합물
ES2811136T3 (es) * 2015-08-04 2021-03-10 Rigel Pharmaceuticals Inc Compuestos de benzazol y métodos para obtener y usar los compuestos
EP3532164A4 (en) 2016-10-28 2020-10-07 Children's Hospital Medical Center TREATMENT OF DISEASES RELATED TO ACTIVATED IRAQ
KR102633530B1 (ko) 2017-03-31 2024-02-02 오리진 온콜로지 리미티드 혈액 장애를 치료하기 위한 화합물 및 조성물
EP3704108B1 (en) 2017-10-31 2024-04-24 Curis, Inc. Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer

Also Published As

Publication number Publication date
HUE062648T2 (hu) 2023-11-28
BR112019018991A2 (pt) 2020-04-14
US20220339161A1 (en) 2022-10-27
PT3600270T (pt) 2023-07-25
RS64411B1 (sr) 2023-09-29
HRP20230657T1 (hr) 2023-10-13
JP2023154005A (ja) 2023-10-18
ES2950764T3 (es) 2023-10-13
HRP20230657T8 (hr) 2023-11-10
EP4252853A3 (en) 2023-12-13
US20210290628A1 (en) 2021-09-23
KR20190130023A (ko) 2019-11-20
EP3600270B1 (en) 2023-06-14
SI3600270T1 (sl) 2023-10-30
CA3056893A1 (en) 2018-10-04
SG11201908171TA (en) 2019-10-30
EA201992322A3 (ru) 2020-09-30
JP2020512343A (ja) 2020-04-23
AU2018242623B2 (en) 2024-05-02
EP3600270A4 (en) 2020-08-26
EP3600270A2 (en) 2020-02-05
DK3600270T3 (da) 2023-07-10
EP4252853A2 (en) 2023-10-04
KR102633530B1 (ko) 2024-02-02
WO2018178947A2 (en) 2018-10-04
IL293783A (en) 2022-08-01
IL269536A (en) 2019-11-28
IL293783B1 (en) 2023-09-01
IL269536B (en) 2022-07-01
PL3600270T3 (pl) 2023-09-25
IL305150A (en) 2023-10-01
NZ757707A (en) 2023-09-29
MX2019011158A (es) 2019-10-17
US11419875B2 (en) 2022-08-23
EA201992322A2 (ru) 2020-07-31
JP7333136B2 (ja) 2023-08-24
FI3600270T3 (fi) 2023-07-20
IL293783B2 (en) 2024-01-01
PH12019502138A1 (en) 2020-06-29
CN110691589A (zh) 2020-01-14
LT3600270T (lt) 2023-08-25
KR20240019391A (ko) 2024-02-14
AU2018242623A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
MX2022001343A (es) Compuestos y composiciones para tratar trastornos hematologicos.
PH12020550457A1 (en) Compounds and compositions for treating hematological disorders
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
NZ716392A (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
PH12018501413A1 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
MX2016009355A (es) Inhibidores de aril lactama cinasa.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
WO2018039077A8 (en) Therapeutic compounds
WO2016164295A3 (en) Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.